| Time | Topic / Powerpoint Presentation | Presenter |
|---|---|---|
| Thursday, September 9th - Morning Session | ||
| 8:00 am–8:10* am | Welcome and Introduction | Mark Geyer, Ph.D. & Robert Heinssen, Co-Chairs |
| 8:10 am–8:30 am | NIMH's Approaches to Treatment Development | Wayne Fenton, M.D. |
| 8:30 am–8:50 am | Overview of MATRICS and TURNS | Stephen Marder, M.D. |
| 8:50 am–9:20 am | Introduction | Thomas Insel, M.D. |
| 9:20 - 9:50 am | The promises and perils of moving from clinical neuropsychological to cognitive neuroscientific approaches to measuring treatment effects on cognition in schizophrenia | Cameron Carter |
| 9:50 - 10:20 am | Needs and approaches for proof of concept and clinical validation studies of putative treatments for cognitive deficits in schizophrenia | Alan Breier |
| 10:20 - 10:30 a.m. | Coffee Break | |
| 10:30 - 11:00 a.m. | Assessing Dysfunction Using Refined Cognitive Methods | John Jonides |
| 11:00 - 11:30 a.m. | Needs and prospects for preclinical predictors of efficacious treatments for cognitive deficits in schizophrenia | Jim Hagan |
| 11:30 - 12:00 p.m. | Synthesizing schizophrenia: a bottom-up, symptomatic approach | Trevor Robbins |
| 12:15 - 1:00 p.m. | Lunch in Bolger Center | |
| Afternoon Session, Thursday September 9, 2004 | ||
| 1:00 pm–3:00 pm | Early Afternoon Breakout Groups | |
| 1. Biomarkers for Clinical Trials I - Neuroimaging | Cameron Carter & Greg McCarthy, Co-leaders | |
| 2. Distinguishing separable domains of cognition in human and animal studies: What separations are optimal for targeting interventions? | Keith Nuechterlein & Trevor Robbins, Co-leaders | |
| 3. Developing predictive models and establishing a preclinical trials network for assessing treatment effects on cognition in animals | Tony Grace & Lisa Gold, Co-leaders | |
| 4. Impact of emotion and stress on cognition | Deanna Barch & Bruce Cuthbert, Co-leaders | |
| 3:00 pm – 3:30 pm | Coffee Break, move to new rooms | |
| 3:30 pm–5:30 pm | Late Afternoon Breakout Groups | |
| 5.Biomarkers for Clinical Trials II -- Psychophysiology and electrophysiology | Bruce Cuthbert & Judy Ford, Co-leaders | |
| 6. Emerging frontiers in behavioral measures of cognition | Jonathon Cohen & Jon Jonides, Co-leaders | |
| 7. Social cognition: human and animal paradigms | Michael Green & Berend Olivier, Co-leaders | |
| 8. Biomarkers for Clinical Trials III -- Genetics and Genomics | Dan Weinberger & Linda Brady, Co-leaders | |
| Friday, September 10th - Reports from Breakout Group Co-leaders, including 3 top priority needs in each area | ||
| 8:00 - 10:00 a.m. | Group
1 - Biomarkers for Clinical Outcomes: Neuroimaging |
|
| 10:00 - 10:30 a.m. | Coffee Break | |
| 10:30 - 12:30 p.m. | Group
4 - Impact of Emotion and Stress on Cognition Group 5 - Biomarkers for Clinical Trials II -- Psychophysiology and electrophysiology Group 7 - Social Cognition in Schizophrenia Group 8 - Biomarkers for Clinical Trials III – Genetics & Genomics |
|
| 12:30 - 1:30 p.m. | Working Lunch: Discussions to focus on areas of consensus and divergence | |
| 1:30 - 3:30 p.m. | Panel Discussion - Chairs, Speakers, and Breakout Group Co-leaders A. Reactions from the Thursday morning Speakers B. Discussion/resolution of overlaps and relationships among Breakout Groups C. Generation of priorities for a research agenda: new approaches to the assessment and treatment of cognitive deficits in schizophrenia |
|
Contact matricsassessment@gmail.com for questions or comments about the MATRICS program and see our website - www.matricsinc.org - for details regarding the MATRICS Consensus Cognitive Battery (MCCB).
Contact support@matrics.ucla.edu for questions or comments about with this web site.
TURNS Home Page | UCLA Home Page | Terms of Use | Disability Resources at UCLA
| Revised: Sunday, 09-Jan-2005 21:13:18 PST |